Core Viewpoint - 中工国际 is actively expanding its presence in the oil and gas engineering sector, particularly in the Middle East, with significant project achievements and strategic plans for growth [1]. Group 1: Company Developments - 中工国际 reported a closing price of 8.47 yuan on July 4, 2025, with a decrease of 1.28% and a trading volume of 156,800 shares, amounting to a transaction value of 133 million yuan [1]. - The company has made significant strides in the oil and gas sector, particularly with the successful launch of the oil and gas central processing facility project in Iraq, valued at approximately 1 billion USD, which set records for the shortest construction period and achieved 18 million consecutive safe working hours [1]. - In 2024, 中工国际 signed another contract for the Iraq Nine District Well Project, which was successfully launched in the first quarter of 2025, further enhancing its brand influence in the Middle Eastern oil and gas engineering industry [1]. Group 2: Financial and Trading Information - On July 4, 2025, 中工国际 experienced a net outflow of 14.81 million yuan from major funds, while speculative funds saw a net inflow of 10.74 million yuan, and retail investors contributed a net inflow of 4.06 million yuan [1].

Group 1 - The core viewpoint of the news is that Zhonggong International (002051) is actively engaging in AI medical applications and has a strong market position in medical building design, while also announcing a cash dividend plan for shareholders [1][2][4] Group 2 - As of July 3, 2025, Zhonggong International's stock closed at 8.58 yuan, with a slight increase of 0.12%, a turnover rate of 1.18%, a trading volume of 145,700 shares, and a transaction amount of 125 million yuan [1] - The company has a significant presence in the medical building sector, participating in the construction of over 25% of China's top 100 hospitals, and is focusing on digital transformation in building design, including AI technologies [1] - The company announced a cash dividend of 1.25 yuan per 10 shares for the fiscal year 2024, with the record date set for July 9, 2025, and the ex-dividend date on July 10, 2025 [2][4] - On July 3, 2025, the net inflow of main funds into Zhonggong International was 6.5258 million yuan, while retail investors saw a net outflow of 9.1745 million yuan [1][4]

Core Viewpoint - The company has approved a profit distribution plan for the fiscal year 2024, which includes a cash dividend of 1.25 RMB per 10 shares for all shareholders, with specific tax considerations for different types of investors [1][2]. Profit Distribution Plan - The profit distribution plan was approved at the annual shareholders' meeting on May 30, 2025, and is based on the total share capital as of December 31, 2024 [1]. - The cash dividend will be distributed as follows: 1.25 RMB per 10 shares before tax, and 1.125 RMB for certain investors after tax deductions [2]. - The distribution will be executed within two months of the approval date, and the total share capital has not changed since the announcement [1][2]. Tax Considerations - Different tax rates apply based on the type of shareholder, with specific provisions for Hong Kong investors and domestic investors holding different types of shares [2]. - The tax obligations for individual investors will be calculated based on their holding period, with no tax due for shares held over one year [2]. Shareholder Registration and Distribution Method - The record date for shareholders eligible for the dividend is July 9, 2025, and the distribution will occur on July 10, 2025 [3]. - Cash dividends will be directly credited to the shareholders' accounts through their custodial securities companies [3]. Consultation and Documentation - The company has provided contact information for inquiries regarding the profit distribution [4].

证券代码：002051 证券简称：中工国际 公告编号：2025－034 中工国际工程股份有限公司 2024 年度分红派息实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、股东大会审议通过利润分配方案情况 中工国际工程股份有限公司（以下简称"公司"）2024 年度利 润分配方案于2025年5月30日经公司2024年度股东大会审议通过， 公司 2024 年度权益分派方案为：以 2024 年 12 月 31 日公司总股本 1,237,408,937股为基数，向全体股东每 10股派1.25元人民币现金（含 税），剩余未分配利润滚存至下年度。分配预案公布后至实施前，公 司总股本如因增发新股、股权激励行权、可转债转股等原因发生变 动的，将按照现金分红总额固定不变的原则，在利润分配实施公告 中披露按公司最新总股本计算的分配比例。 自分配方案披露至实施期间，公司股本总额未发生变化。 本次实施的分配方案与股东大会审议通过的分配方案及其调整 原则是一致的。 【注：根据先进先出的原则，以投资者证券账户为单位计算持股 期限，持股1个月（含1个月）以内，每10股补缴税款0. ...

Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]

Core Points - The company has signed a comprehensive engineering consulting service contract for the Hebei Handan Million Chicken Agricultural Technology Industrial Park, with a total contract value of 175.44 million yuan [1][2][4] - The project involves various consulting services including project management, engineering surveying, planning and design, supervision, cost consulting, bidding agency, financing consulting, and other specialized evaluation consulting [1][2] - The company will undertake a portion of the contract amounting to 131.05 million yuan, which represents 1.07% of the company's projected total revenue for 2024 [4] Contract Details - The contract is between Shenzhen Chenkai Investment Holdings Co., Ltd. as the client and a consortium led by Beijing Xing International Engineering Management Co., Ltd. [2][3] - The service period extends from the signing of the contract until the project completion and acceptance [3] - The consortium members are jointly responsible for providing the consulting services and bear joint liability [3] Impact on the Company - The execution of this contract is expected to enhance the company's professional technical level, comprehensive performance capabilities, and market expansion ability in the domestic engineering consulting sector [4] - The project is significant in scale and contract value, indicating the company's strong position in the engineering consulting industry [4]

Company Announcements - Jihua Group's existing product system does not involve brain-computer interface related fields [1] - Prit's plan to invest 1 billion yuan to build a plastic modification materials headquarters and R&D manufacturing base in South China [1][2] - Lian De Equipment won a contract worth 157 million yuan for BOE's 8.6 generation AMOLED production line project [1][2] - Jiadu Technology plans to issue shares (H-shares) overseas and list on the Hong Kong Stock Exchange [1][2] - Longdi Group intends to acquire no more than 20.1667% equity in Jujia Technology [1][4] - New Zhonggang plans to repurchase shares worth 40 million to 80 million yuan [1][4] - Xiaogoods City expects a net profit increase of 12.57% to 17.40% in the first half of the year [1][4] - Sinopec Capital plans to reduce its holdings by no more than 3.5256 million shares in Haizheng Materials through block trading [1][4] - Lihua Co., Ltd. intends to reduce its holdings by no more than 3.00% [1][4] - Zhimin Da plans to raise no more than 213 million yuan through a private placement [1][5] - Xiangtong Co. plans to issue corporate bonds not exceeding 4 billion yuan [1][5] Performance Forecasts - Hanyu Pharmaceutical expects a half-year profit of 142 million to 162 million yuan, turning a profit compared to the previous year [4] - Taotao Automotive anticipates a net profit increase of 70.34% to 97.81% in the first half of the year [4] - Weichai Heavy Machinery expects a net profit increase of 40% to 60% in the first half of the year [4] Shareholding Changes - Lihua Co., Ltd.'s actual controller Cheng Lili and his concerted actors plan to reduce their holdings by no more than 3.00% [4] - He Shi Eye Hospital's Advanced Manufacturing Fund plans to reduce its holdings by no more than 2% [4] - Haitan Ruisheng's shareholder He Lin and his concerted actors plan to reduce their holdings by no more than 2.9463% [4] - Sinopec Capital plans to reduce its holdings by no more than 3.5256 million shares in Haizheng Materials [4] Other Announcements - Zhimin Da plans to raise no more than 213 million yuan through a private placement [5] - Yuyuan Co. plans to issue corporate bonds not exceeding 40 billion yuan [5] - Jinhongshun has terminated the planning of a major asset restructuring [5]

Core Viewpoint - Multiple listed companies in the Shanghai and Shenzhen stock markets have announced significant updates, including changes in financing, business performance, and strategic decisions, which may impact investor sentiment and market dynamics [1]. Financing and Restructuring - Guanhao Biological has withdrawn its application for refinancing, leading to the termination of the review process by the Shenzhen Stock Exchange [3]. - Jinhongshun has terminated its major asset restructuring plan due to a lack of consensus among parties involved [6]. - Yuyuan Co. plans to issue bonds not exceeding 40 billion yuan to adjust its debt structure and replenish working capital [23]. Business Performance and Uncertainties - Aored has highlighted significant uncertainties in its computing power leasing services due to heavy asset investment and potential market fluctuations [4]. - Guoyao Modern intends to publicly transfer 51% of its subsidiary Guoyao Hason's shares, as the subsidiary has been underperforming with continuous losses since 2021 [5]. - Chengbang Co. reported that its subsidiary, Xinchun Electronics, has a small business scale and faces intense competition in the semiconductor storage industry, with projected revenues of 111 million yuan and a net profit of 933,800 yuan for 2024 [9]. Stock Market Activity - Alloy Investment announced a change in its controlling shareholder to Jiuzhou Hengchang, with stock trading resuming on July 1 [7]. - Changcheng Military Industry reported significant stock price volatility, with a cumulative increase of over 100% in the last 10 trading days, indicating potential irrational market behavior [8]. Earnings Forecasts - Hanyu Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, recovering from a loss in the previous year, driven by international business growth [12]. - Taotao Vehicle anticipates a net profit increase of 70.34% to 97.81% for the same period, reflecting strong sales performance [13]. - Weichai Heavy Machinery projects a net profit increase of 40% to 60%, benefiting from industry policy support and demand growth [15]. Major Contracts and Projects - China Railway has won contracts for overseas construction projects totaling approximately 5.343 billion yuan [17]. - Zhonggong International has signed a 175 million yuan engineering consulting service contract [18]. - Hezhan Energy has entered into a 177 million yuan contract for the sale of steel-concrete towers [19].

证券代码：002051 证券简称：中工国际 公告编号：2025－033 中工国际工程股份有限公司经营合同公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 2025 年 6 月 30 日，中工国际工程股份有限公司（以下简称公司） 下属全资公司京兴国际工程管理有限公司（以下简称京兴国际）、下 属全资公司中国中元国际工程有限公司（以下简称中国中元）、下属 控股子公司中元国际（长春）高新建筑设计院有限公司（以下简称中 元长春），与丰汇（天津）项目管理有限公司（以下简称丰汇（天津）） 组成联合体，与深圳宸可投资控股有限公司签署了河北省邯郸市百万 蛋鸡农业科技产业园全过程工程咨询服务合同。 一、合同主要内容 河北省邯郸市百万蛋鸡农业科技产业园全过程工程咨询服务合 同金额为 17,544.03 万元，该项目位于河北省邯郸市，项目内容为咨 询人向委托人提供全过程工程咨询服务，包括：项目管理、工程勘察、 工程规划及设计、工程监理、全过程造价咨询、招标代理、融资咨询 和其他专项评价咨询。其中，京兴国际（联合体牵头人）、中国中元和 中元长春主要承担项目管理、工程监理、其他专项评 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Zhonggong International, indicating a decline in revenue but an increase in net profit [1][2] - As of June 30, Zhonggong International's closing price was 8.63 yuan, with a rolling PE ratio of 28.44 times and a total market value of 10.679 billion yuan [1] - The company ranks 50th in the engineering construction industry, which has an average PE ratio of 13.40 times and a median of 20.14 times [1][2] Group 2 - The company has six institutional shareholders, including one fund, holding a total of 80,141,280 shares valued at 6.467 billion yuan [1] - Zhonggong International's main business includes design consulting, engineering contracting, advanced engineering technology equipment development, and engineering investment and operation [1] - The company has received over 300 national and provincial-level scientific and technological achievement awards and holds a first-class engineering design qualification for cableways [1] Group 3 - In the latest quarterly report for Q1 2025, the company reported an operating income of 2.183 billion yuan, a year-on-year decrease of 7.61%, while net profit was 131 million yuan, a year-on-year increase of 12.17%, with a sales gross margin of 19.72% [1]